BIRC5 and neoplasm: Because the biomarkers associated with tumour proliferation are significant factors in advanced-stage NSCLCs (Huang et al, 2005), the level of the survivin-deltaEx3 gene expression could thus affect the clinical impact of NSCLCs, especially in the advanced stages.